In order to treat neuroblastoma, the study used computational methods to create and assess novel PROTACs that target BRD4, a protein involved in gene regulation and cell functioning. Using chemical modifications to create a PROTAC library and molecular docking simulations, the study found that PROTAC II was the most efficient at binding to E3 ligase and BRD4 proteins. This interaction stimulates BRD4's ubiquitination and subsequent destruction, which stops neuroblastoma cells from proliferating. The results imply that these engineered PROTACs have the potential to be developed into effective, affordable, and less side-effectprone therapeutic approaches for the treatment of neuroblastoma. To validate these computational results, more validations from experiments and molecular dynamics simulations are required.